Pancreatic Cancer Research

ResearcherJohns Hopkins UniversityActive in the last 2 years

Nilofer Saba Azad

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9613-3988; OpenAlex author ID A5060219345, A5083077241, A5108833526, A5109044620, A5109449629, A5112291086; NIH RePORTER profile ID 10520750. Sources: ClinicalTrials.gov.

Their work

Papers
27 (first author 5, last author 4)
Trials
8 (principal investigator on 8)
Grants
3
Labs led
1
Collaborators
133
Papers, trials and grants by year

2013: 1 trial · 2014: 1 trial, 1 grant · 2015: none · 2016: 2 papers · 2017: 3 papers, 1 trial · 2018: none · 2019: none · 2020: 2 papers, 2 trials · 2021: 5 papers · 2022: 2 papers, 1 trial · 2023: 1 paper, 1 trial · 2024: 3 papers, 1 trial · 2025: 4 papers, 1 grant · 2026: 5 papers, 1 grant

Papers 27

  1. Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. Co-author DOI 10.1038/s41467-026-68324-4↗
  2. Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial Co-author DOI 10.1038/s41467-026-71968-x↗
  3. Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer. Co-author DOI 10.1056/nejmoa2505783↗
  4. Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer. Co-author DOI 10.1056/nejmoa2605555↗
  5. First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. Co-author DOI 10.1158/2159-8290.cd-25-2245↗
  6. Cancer Susceptibility Gene Testing in Patients With Pancreatic Ductal Adenocarcinoma: Implementation in a Cancer Center Oncology Clinic. Co-author DOI 10.1200/po-24-00494↗
  7. Immune-Based Strategies for Pancreatic Cancer in the Adjuvant Setting. First author DOI 10.3390/cancers17071246↗
  8. ME3BP-7 is a targeted cytotoxic agent that rapidly kills pancreatic cancer cells expressing high levels of monocarboxylate transporter MCT1. Co-author DOI 10.7554/elife.94488↗
  9. ME3BP-7 is a targeted cytotoxic agent that rapidly kills pancreatic cancer cells expressing high levels of monocarboxylate transporter MCT1 Co-author DOI 10.7554/elife.94488.3↗
  10. Entinostat in combination with nivolumab in metastatic pancreatic ductal adenocarcinoma: a phase 2 clinical trial. Last author DOI 10.1038/s41467-024-52528-7↗
  11. Unlocking the promise of RAS inhibition in pancreatic cancer. First author DOI 10.1038/s41575-024-00951-y↗
  12. A case of adenosquamous pancreatic cancer with a KRAS G12C mutation with an exceptional response to immunotherapy. Co-author DOI 10.18632/oncotarget.28659↗
  13. Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer. Co-author DOI 10.1158/2767-9764.crc-23-0230↗
  14. A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence. Last author DOI 10.1186/s13148-022-01367-8↗
  15. RAD51B Harbors Germline Mutations Associated With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1200/po.21.00404↗
  16. Next-generation immunotherapy for pancreatic ductal adenocarcinoma: navigating pathways of immune resistance. First author DOI 10.1007/s10555-021-09981-3↗
  17. Correction to: Next-generation immunotherapy for pancreatic ductal adenocarcinoma: navigating pathways of immune resistance. First author DOI 10.1007/s10555-021-09999-7↗
  18. Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017. Co-author DOI 10.1016/j.canlet.2020.10.039↗
  19. Implantation of a neoantigen-targeted hydrogel vaccine prevents recurrence of pancreatic adenocarcinoma after incomplete resection. Co-author DOI 10.1080/2162402x.2021.2001159↗
  20. Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectabl… Co-author DOI 10.1158/1078-0432.ccr-20-2974↗
  21. Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future. Last author DOI 10.1016/s1470-2045(19)30795-8↗
  22. A Phase I Study of Dinaciclib in Combination With MK-2206 in Patients With Advanced Pancreatic Cancer. Last author DOI 10.1111/cts.12802↗
  23. Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer. Co-author DOI 10.1002/cam4.1104↗
  24. ACR Appropriateness Criteria® Resectable Pancreatic Cancer. Co-author DOI 10.1097/coc.0000000000000370↗
  25. Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer. Co-author DOI 10.18632/oncotarget.17237↗
  26. A phase 1 dose-escalation study of NEO-102 in patients with refractory colon and pancreatic cancer. First author DOI 10.1007/s00280-016-3108-5↗
  27. Longer Course of Induction Chemotherapy Followed by Chemoradiation Favors Better Survival Outcomes for Patients With Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/coc.0000000000000022↗

Trials 8

  1. KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer Principal investigator NCT06411691↗
  2. Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal Cancer Principal investigator NCT04799431↗
  3. Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer Principal investigator NCT05013216↗
  4. INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer Principal investigator NCT04116073↗
  5. Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal a… Principal investigator NCT04117087↗
  6. A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic … Principal investigator NCT03250273↗
  7. Trial to Improve Outcomes in Patients With Resected Pancreatic Cancer (Azacitidine) Principal investigator NCT01845805↗
  8. Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery Principal investigator NCT01783171↗

Grants 3

  1. Optimization of an active mutant KRAS peptide vaccine in colorectal cancer R01CA296410↗
  2. Administrative Core P01CA247886↗
  3. Targeting RAS signaling with CDK and AKT inhibition in pancreatic cancer R21CA172997↗

Closest collaborators

The 25 strongest of 133 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Neeha Zaidi · 5 shared papers, 1 shared grant, 2021–2026 · strength 2.15
  2. Elizabeth M. Jaffee · 9 shared papers, 1 shared grant, 2017–2026 · strength 1.98
  3. Lei Zheng · 8 shared papers, 1 shared grant, 2016–2025 · strength 1.46
  4. Daniel A. Laheru · 11 shared papers, 2016–2026 · strength 1.38
  5. Dung Thi Le · 7 shared papers, 1 shared grant, 2016–2025 · strength 1.31
  6. Thatcher Ross Heumann · 5 shared papers, 2021–2026 · strength 1.07
  7. Saurav Daniel Haldar · 4 shared papers, 2024–2026 · strength 1.04
  8. Marina Baretti · 6 shared papers, 2021–2026 · strength 0.96
  9. Mark M. Yarchoan · 6 shared papers, 2017–2026 · strength 0.89
  10. Won Jin Ho · 5 shared papers, 2021–2026 · strength 0.83
  11. Katherine M. Bever · 5 shared papers, 2021–2026 · strength 0.83
  12. Hao Wang · 4 shared papers, 2023–2026 · strength 0.75
  13. Luciane Tsukamoto Kagohara · 4 shared papers, 2021–2026 · strength 0.68
  14. Amanda L. Huff · 4 shared papers, 2021–2026 · strength 0.68
  15. Robert A. Anders · 5 shared papers, 2021–2026 · strength 0.64
  16. Jin Peng He · 6 shared papers, 2017–2025 · strength 0.62
  17. Ana De Jesus‐Acosta · 7 shared papers, 2016–2023 · strength 0.58
  18. Kai-li Liang · 1 shared paper, 2025 · strength 0.54
  19. Elana Judith Fertig · 3 shared papers, 2024–2026 · strength 0.53
  20. Andrew Eugene Hendifar · 2 shared papers, 2024–2026 · strength 0.51
  21. Michael Goggins · 3 shared papers, 2017–2026 · strength 0.48
  22. Brian Matthew Wolpin · 2 shared papers, 2026 · strength 0.46
  23. Ignacio Garrido‐Laguna · 2 shared papers, 2026 · strength 0.46
  24. Hassan Sinan · 2 shared papers, 2025–2026 · strength 0.42
  25. Bert Vogelstein · 2 shared papers, 2025 · strength 0.41

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.